The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification

Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected t...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 24; no. 1; p. 120
Main Authors Weng, Lijuan, Zhou, Jianliang, Guo, Shenchao, Xu, Nong, Ma, Ruishuang
Format Journal Article
LanguageEnglish
Published England BioMed Central 30.03.2024
BMC
Subjects
Androgen receptors
Androgens
Angiogenesis
Breast cancer
Cancer therapies
Cell cycle
Classification
Clinical trials
Cytokines
Epidermal growth factor
Gene expression
Genomes
Kinases
Medical prognosis
Metabolomics
Metastases
MicroRNAs
Molecular subtyping
Mutation
Precision medicine
Transcriptomics
Triple-negative breast cancer
Tumors
Molecular subtyping
Precision medicine
Triple-negative breast cancer
Online AccessGet full text

Cover

More Information
Summary:Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-024-03261-0